Elekta AB (publ) (EKTAY)
| Market Cap | 2.17B +1.8% |
| Revenue (ttm) | 1.93B -4.3% |
| Net Income | -4.51M |
| EPS | -0.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 13.29 |
| Dividend | 0.15 (2.70%) |
| Ex-Dividend Date | Mar 6, 2026 |
| Volume | 500 |
| Average Volume | 2,826 |
| Open | 5.65 |
| Previous Close | 5.99 |
| Day's Range | 5.61 - 5.66 |
| 52-Week Range | 4.35 - 6.93 |
| Beta | 1.09 |
| RSI | 39.86 |
| Earnings Date | Mar 5, 2026 |
About Elekta AB
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear accelerator and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo that delivers offline and online adaptive radiation therapy; Elekta Versa HD, a brain metastases solution; Elekta Harmony; and Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs, as wel... [Read more]
Financial Performance
In fiscal year 2025, Elekta AB's revenue was 18.02 billion, a decrease of -0.57% compared to the previous year's 18.12 billion. Earnings were 237.00 million, a decrease of -81.80%.
Financial numbers in SEK Financial StatementsNews
Elekta AB (EKTAF) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst Currency Challenges
Elekta AB (EKTAF) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst Currency Challenges
Q3 2026 Elekta AB (publ) Earnings Call Transcript
Q3 2026 Elekta AB (publ) Earnings Call Transcript
ZAP Surgical Deals Two More Blows to Elekta in IP Suit, Removing Barriers to Mass Adoption of the ZAP-X Radiosurgery Platform
SAN CARLOS, Calif.--(BUSINESS WIRE)--ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, has achieved significant legal victories in its ongoing patent litigation agains...
St George's Cancer Care Centre Becomes First Elekta Unity Site to Integrate ClearCalc
NEW YORK & CHRISTCHURCH, New Zealand--(BUSINESS WIRE)--St George's Cancer Care Centre is the first cancer center in the world to leverage ClearCalc from Radformation with Elekta's MR-Linac technology.
Elekta: Interim report, May-January 2021/22
STOCKHOLM, Feb. 24, 2022 /PRNewswire/ -- The demand for Elekta's solutions continued to be strong in the third quarter, the fifth consecutive quarter with underlying order growth, resulting in Elekta'...
Elekta announces preliminary third quarter results
STOCKHOLM, Feb. 14, 2022 /PRNewswire/ -- Elekta (EKTA-B.ST) today published preliminary financial results for the third quarter 2021/22. The demand for Elekta's precision radiation medicine solutions ...
Invitation to the presentation of Elekta's third quarter 2021/22
STOCKHOLM, Feb. 4, 2022 /PRNewswire/ -- Elekta (EKTA-B.ST) invites analysts and investors to a presentation of the third quarter 2021/22 at 10:00 a.m. CET on February 24.
Elekta increases customer focus with direct presence in Philippines
STOCKHOLM, Feb. 2, 2022 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that it has established an office in the Philippines' capital, Manila, to offer new and existing customers superior service, ...
Elekta to appoint Tobias Hägglöv as Chief Financial Officer
STOCKHOLM, Jan. 7, 2022 /PRNewswire/ -- Elekta (STO: EKTA-B) announced today that it will appoint Tobias Hägglöv as Chief Financial Officer effective February 1, 2022, taking over from Johan Adebäck. ...
Elekta's new sustainability-linked bond oversubscribed
STOCKHOLM, Dec. 3, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that it has issued SEK 1.5 billion senior unsecured sustainability-linked bonds under its Medium Term Note Program (MTN-Progr...
More cancer patients in Africa to benefit from advanced radiation therapy with Elekta Unity MR-Linac
STOCKHOLM, Nov. 25, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that its latest African order for Elekta Unity MR-Linac comes less than six months after the company introduced its ACCESS 2...
Elekta: Interim report, May-October 2021/22
STOCKHOLM, Nov. 25, 2021 /PRNewswire/ -- The increasing need for investments in cancer care and radiotherapy across the globe supported a gradual market recovery during the quarter. Our orders grew wi...
Invitation to the presentation of Elekta's second quarter 2021/22
STOCKHOLM, Nov. 4, 2021 /PRNewswire/ --Elekta (EKTA-B.ST) invites analysts and investors to a presentation of the second quarter 2021/22 at 10:00 a.m. CET on November 25.
Elekta establishes a framework for sustainability-linked bonds
STOCKHOLM, Oct. 29, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that it has established a Sustainability-Linked Bond Framework (SLB Framework) for issues of sustainability-linked bonds und...
Elekta receives initial investment grade rating from S&P Global Ratings
STOCKHOLM, Oct. 26, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that it has received an investment grade (IG) rating from S&P Global Ratings (S&P). S&P has assigned a BBB- rating to Elekta...
Elekta acquires Turkish distributor to strengthen market position
STOCKHOLM, Sept. 2, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that it has acquired its long-time partner and Turkish distributor of neurosurgery solutions, Özyürek Mümessillik ve Dış Tic...
Elekta's Board announces establishment of philanthropic Elekta Foundation
STOCKHOLM, Aug. 26, 2021 /PRNewswire/ -- At its Annual General Meeting on August 25, Elekta's (EKTA-B.ST) shareholders approved the Board of Directors' proposal to establish the Elekta Foundation. The...
Report from the Annual General Meeting 2021 in Elekta
STOCKHOLM, Aug. 25, 2021 /PRNewswire/ -- Elekta AB (publ) has held its Annual General Meeting on 25 August 2021. In light of the extraordinary situation prevailing as a result of Covid-19, the Meeting...
Elekta to address Indonesia's cancer care gap with direct presence
STOCKHOLM, Aug. 25, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that is has established permanent legal entity in Indonesia's capital, Jakarta in order to address the unmet need for high q...
Invitation to the presentation of Elekta's first quarter 2021/22
STOCKHOLM, Aug. 11, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) invites analysts and investors to a presentation of the first quarter 2021/22 at 10:00 a.m. CEST on August 25.
Data from 14 leading cancer centers presented at AAPM highlight global adoption of Elekta Unity MR-Linac
ATLANTA, July 23, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced the presentation of 36 abstracts demonstrating the technical capabilities and clinical utility of the Elekta Unity MR-Linac. T...
Notice to the Annual General Meeting of Elekta AB (publ)
STOCKHOLM, July 21, 2021 /PRNewswire/ -- The shareholders of Elekta AB (publ), reg. no 556170-4015 are hereby convened to the Annual General Meeting to be held on Wednesday 25 August 2021.
Elekta optimizes treatment times for cancer patients via proactive service innovation
STOCKHOLM, July 7, 2021 /PRNewswire/ -- For the last several years, Elekta (EKTA-B.ST) has invested substantially in digitized service solutions to keep critical treatment machines up and running at c...
Elekta radiotherapy system designed for changing cancer landscape now available for U.S. patients
ATLANTA, June 17, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that its Elekta Harmony* radiation therapy system recently received U.S. FDA 510(k) clearance, paving the way for U.S. clinics...
Elekta's new strategy to focus on growth and access to radiation therapy
STOCKHOLM, June 7, 2021 /PRNewswire/ -- At Elekta's (EKTA-B.ST) Capital Markets Day, CEO, Gustaf Salford, and members from his executive management team introduced the company's mid-term strategy, cal...